Pages
Related News
04May
Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
0 CommentsStevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
30May
Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
0 CommentsStevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
15Apr
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator
0 Comments• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of... Read More →
18Jan
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
0 CommentsStevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
18Dec
Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
0 CommentsCollaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
Tweets
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take… https://t.co/A1hedx6tYy
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic appro… https://t.co/xOlDJ1kTe9
Comments are closed.